The DOI matches its Crossref record.
Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy
Open accessAbstract
BACKGROUND: In a retrospective study of Southwestern Oncology Group (SWOG)‐S8710/INT‐0080 (radical cystectomy [RC] alone vs 3 cycles of neoadjuvant chemotherapy [NC] with methotrexate, vinblastine, doxorubicin, and cisplatin before RC for bladder cancer), factors found to be associated with improved overall survival (OS) included pathologic complete response, defined as P0; treatment with NC; completion of RC with negative surgical margins; and ≥10 pelvic lymph nodes (LNs) removed. METHODS: The authors used stratified Cox regression to retrospectively study the association of quality of pathologic response after RC with OS in the subset of S8710 patients who received NC and RC with negative surgical margins. RESULTS: Of 154 patients who received NC, 68 (44.2%) were <P2 (P0, Pa, P1, or carcinoma in situ [CIS]) at RC, 46 (29.9%) were P0, and the remainder had P2+ disease or did not undergo RC. In 115 patients who had RC with negative surgical margins, compared with P0 patients, those with residual Pa, P1, or CIS appeared to have worse OS (P = .054); OS was significantly worse for patients with residual P2+ disease (P = .0006). LN–positive (LN+) disease was found to be associated with worse OS than LN–negative (LN−) disease (P = .0005). Patients with LN− disease (ie, those with <10 LNs removed) appeared to have inferior OS compared with those with 10+ LNs removed (P = .079). The combination of pre‐NC clinical stage and post‐RC pathologic stage was found to be predictive of OS (P < .0001). CONCLUSIONS: NC and RC with negative surgical margins for bladder cancer followed by pathologic P0 and LN− disease were found to correlate with improved OS. A combination of baseline clinical stage and post‐RC pathologic stage may better predict OS. Cancer 2009. © 2009 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Treatment of muscle‐invasive and advanced bladder cancer in 2020
Patel, V. G., Oh, W. K., & Galsky, M. D. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21631 · Cited by 1,014
Necchi, A., Anichini, A., Raggi, D., Briganti, A., Massa, S., Lucianò, R., Colecchia, M., Giannatempo, P., Mortarini, R., Bianchi, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.01148 · Cited by 741
Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma
Van Allen, E. M., Mouw, K. W., Kim, P., Iyer, G., Wagle, N., Al-Ahmadie, H., Zhu, C., Ostrovnaya, I., Kryukov, G. V., O'Connor, K. W., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0623 · Cited by 620
Plimack, E. R., Dunbrack, R. L., Brennan, T. A., Andrake, M. D., Zhou, Y., Serebriiskii, I. G., Slifker, M., Alpaugh, K., Dulaimi, E., Palma, N., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.07.009 · Cited by 519
Petrelli, F., Coinu, A., Cabiddu, M., Ghilardi, M., Vavassori, I., & Barni, S. (2014) · European Urology · doi:10.1016/j.eururo.2013.06.049 · Cited by 331
Necchi, A., Raggi, D., Gallina, A., Madison, R., Colecchia, M., Lucianò, R., Montironi, R., Giannatempo, P., Farè, E., Pederzoli, F., et al. (2020) · European Urology · doi:10.1016/j.eururo.2019.10.026 · Cited by 325
Gao, J., Navai, N., Alhalabi, O., Siefker-Radtke, A., Campbell, M. T., Tidwell, R. S., Guo, C. C., Kamat, A. M., Matin, S. F., Araujo, J. C., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1086-y · Cited by 318
Rosenblatt, R., Sherif, A., Rintala, E., Wahlqvist, R., Ullén, A., Nilsson, S., & Malmström, P.-U. (2012) · European Urology · doi:10.1016/j.eururo.2011.12.010 · Cited by 294
Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
Zargar, H., Espiritu, P. N., Fairey, A. S., Mertens, L. S., Dinney, C. P., Mir, M. C., Krabbe, L.-M., Cookson, M. S., Jacobsen, N.-E., Gandhi, N. M., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.09.007 · Cited by 294
Kamat, A. M., Hegarty, P. K., Gee, J. R., Clark, P. E., Svatek, R. S., Hegarty, N., Shariat, S. F., Xylinas, E., Schmitz-Dräger, B. J., Lotan, Y., et al. (2013) · European Urology · doi:10.1016/j.eururo.2012.09.057 · Cited by 263
Metadata
- Authors
- Sonpavde, G., Goldman, B. H., Speights, V. O., Lerner, S. P., Wood, D. P., Vogelzang, N. J., Trump, D. L., Natale, R. B., Grossman, H. B., & Crawford, E. D.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2009-06-10
- Volume
- 115
- Issue
- 18
- Pages
- 4104-4109
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2073175347
- Cited by
- 195
- References
- 0
- FWCI
- 7.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.